CSIMarket
 
Veru Inc   (VERU)
Other Ticker:  
 
 
Price: $0.6400 $0.03 5.768%
Day's High: $0.6598 Week Perf: 16.32 %
Day's Low: $ 0.59 30 Day Perf: 31.23 %
Volume (M): 1,161 52 Wk High: $ 2.58
Volume (M$): $ 743 52 Wk Avg: $1.01
Open: $0.60 52 Wk Low: $0.36



 Market Capitalization (Millions $) 54
 Shares Outstanding (Millions) 85
 Employees 1,300
 Revenues (TTM) (Millions $) 16
 Net Income (TTM) (Millions $) -93
 Cash Flow (TTM) (Millions $) -71
 Capital Exp. (TTM) (Millions $) 1

Veru Inc
Veru Inc is a biopharmaceutical company that primarily focuses on developing and commercializing drugs for men's and women's health. They work to address unmet medical needs in areas such as prostate cancer, male infertility, and sexual health. The company also offers a range of consumer healthcare products. Veru's goal is to provide innovative and effective solutions to enhance the well-being and quality of life for patients.


   Company Address: 2916 N. Miami Avenue Miami 33127 FL
   Company Phone Number: 509-6897   Stock Exchange / Ticker: NASDAQ VERU
   


Customers Net Income grew by VERU's Customers Net Profit Margin grew to

104.2 %

11.15 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stock Market Announcement

Veru Faces Compliance Concerns as Nasdaq Issues Delinquency Notice

Published Wed, Feb 28 2024 12:15 AM UTC

Veru Faces Delinquency Notice from Nasdaq, Highlighting Compliance Issues
MIAMI, FL, Feb. 27, 2024 - Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company, recently received a delinquency notification letter from the Nasdaq Stock Market LLC regarding its failure to file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023....

Clinical Study

Advancing Muscle Loss Treatment: Veru's FDA Clearance of IND Application for Enobosarm

Published Tue, Feb 6 2024 1:30 PM UTC

In a significant breakthrough for Veru, the pharmaceutical company recently announced the clearance of its Investigational New Drug (IND) application by the FDA. This crucial milestone paves the way for the initiation of Phase 2b clinical trials with Enobosarm, which aims to treat muscle loss associated with weight loss drugs. Furthermore, this trial will explore the combina...

Clinical Study

Muscle-Preserving Marvel: Veru's Enobosarm Revitalizes Weight Loss Approaches

Published Mon, Jan 8 2024 1:30 PM UTC

Veru Inc., a leading biopharmaceutical company dedicated to addressing obesity and other critical medical conditions, recently submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). This milestone application focuses on the development of enobosarm, a novel medication designed to prevent muscle loss while augmenting fat loss i...

Stock Market Announcement

Veru Inc. Raises $33 Million Through Successful Pricing of Common Stock Offering

Published Thu, Dec 14 2023 2:01 PM UTC



Veru Inc., a leading late-stage biopharmaceutical company specializing in the development of innovative treatments for metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome, has announced the pricing of its underwritten public offering. The offering consists of 45,833,333 shares of Veru's common stock at a price of $0.72 per share. Thi...

Veru Inc

Veru Inc. Shatters Expectations with Phenomenal Performance During Fiscal Quarter Ending Sep 30 2023

Veru Inc is a company that recently announced its financial results for the fiscal interval closing on September 30, 2023. The company experienced a surge in revenue by 25.223% to $3.24 million compared to the similar reporting period a year prior. However, Veru Inc also reported a net loss of $-0.11 per share, which represents a growth in the shortfall from $-0.08 per share in the previous year.
Despite the increase in revenue, the company still incurred a loss per share, indicating potential challenges in its operations. The net shortfall for the most recent fiscal period was $-10.794 million, a significant improvement from the deficit of $-41.023 million in the same reporting period a year ago.






 

Veru Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com